Clinical TrialJul 17, 2026, 12:24 PM
Perspective Therapeutics' [212Pb]VMT-α-NET Data Accepted for ESMO 2026
AI Summary
Perspective Therapeutics announced that updated data for its [212Pb]VMT-α-NET program has been accepted for presentation at the European Society of Medical Oncology (ESMO) Congress 2026. The presentation, titled "Cohort level safety and efficacy results for [212Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1–3," will be a Rapid Oral presentation by Dr. Thorvardur Halfdanarson on October 23, 2026. This follows interim clinical data presented at the ASCO Annual Meeting in May 2026, highlighting ongoing progress in the company's radiopharmaceutical development.
Key Highlights
- Updated data for Perspective Therapeutics' [212Pb]VMT-α-NET program accepted for presentation.
- Presentation to occur at the European Society of Medical Oncology (ESMO) Congress 2026.
- ESMO Congress 2026 will take place from October 23 to 27, 2026, in Madrid, Spain.
- Dr. Thorvardur Halfdanarson from Mayo Clinic will present the data.
- Abstract title: "Cohort level safety and efficacy results for [212Pb]VMT-α-NET in advanced SSTR2-expressing neuroendocrine tumors (NETs): Cohorts 1–3."
- Presentation is a Rapid Oral session on October 23, 2026, from 4:25 – 4:30pm CEST.
- ESMO will release further details for regular abstracts on October 19, 2026.
- Interim clinical data from the study (NCT05636618) was previously presented at ASCO in May 2026.
Price Impact
More from CATX